These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16322239)

  • 1. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
    Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
    Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
    Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
    Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
    Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
    Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
    Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ
    Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
    Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y; Opeskin K; Goad J; Williams ED
    Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
    Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
    Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
    Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of osteoblastic cell differentiation by conditioned medium derived from the human prostatic cancer cell line PC-3 in vitro.
    Kido J; Yamauchi N; Ohishi K; Kataoka M; Nishikawa S; Nakamura T; Kadono H; Ikedo D; Ueno A; Nonomura N; Okuyama A; Nagata T
    J Cell Biochem; 1997 Nov; 67(2):248-56. PubMed ID: 9328830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.
    Zhang J; Lu Y; Dai J; Yao Z; Kitazawa R; Kitazawa S; Zhao X; Hall DE; Pienta KJ; Keller ET
    Prostate; 2004 Jun; 59(4):360-9. PubMed ID: 15065084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic mechanical strain increases production of regulators of bone healing in cultured murine osteoblasts.
    Singh SP; Chang EI; Gossain AK; Mehara BJ; Galiano RD; Jensen J; Longaker MT; Gurtner GC; Saadeh PB
    J Am Coll Surg; 2007 Mar; 204(3):426-34. PubMed ID: 17324777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
    Inoue S; Branch CD; Gallick GE; Chada S; Ramesh R
    Mol Ther; 2005 Oct; 12(4):707-15. PubMed ID: 16054437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.